


Irinotecan liposome NAPOLI 3

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects




Other adjustments



Irinotecan liposome NAPOLI 3

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers
Therapeutic Indication: Irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin, for the first-line treatment of metastatic pancreatic adenocarcinoma.
Experimental Arm: Irinotecan liposome + Oxaliplatin, fluorouracil, and leucovorin
Control Arm: Nab-paclitaxel + gemcitabine

